These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 30671338)

  • 1. Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: A radio-pathologic correlation.
    Ueno R; Nemoto M; Uegami W; Fukuoka J; Misawa M
    Respir Med Case Rep; 2019; 26():168-170. PubMed ID: 30671338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 3. Late-onset programmed cell death protein-1 inhibitor-induced pneumonitis after cessation of nivolumab or pembrolizumab in patients with advanced non-small cell lung cancer: a case series.
    Kimura H; Sone T; Araya T; Murata A; Yamamura K; Ohkura N; Hara J; Abo M; Kasahara K
    Transl Lung Cancer Res; 2021 Mar; 10(3):1576-1581. PubMed ID: 33889531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perforation of small intestinal metastasis of lung adenocarcinoma treated with pembrolizumab: a case report.
    Sato S; Senmaru N; Ishido K; Saito T; Poudel S; Muto J; Syouji Y; Hase R; Hirano S
    Surg Case Rep; 2019 Oct; 5(1):166. PubMed ID: 31667679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Late-Onset Acute Pneumonitis Caused by Pembrolizumab Used to Treat Postoperative Recurrence of Squamous Cell Carcinoma-A Case Report].
    Kamiyoshihara M; Yoshikawa R; Igai H; Matsuura N; Yazawa T; Ohsawa F
    Gan To Kagaku Ryoho; 2020 Sep; 47(9):1363-1365. PubMed ID: 33130701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab-Induced Broken Heart Syndrome, Pneumonitis, and Hypophysitis Occurring Concurrently; A Deadly Triad.
    Khan WJ; Asif M; Chaudhry HS; Aslam S; Nadeem I
    J Community Hosp Intern Med Perspect; 2023; 13(3):88-90. PubMed ID: 37877053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
    Sawai Y; Katsuya Y; Shinozaki-Ushiku A; Iwasaki A; Fukayama M; Watanabe K; Nagase T
    Drug Discov Ther; 2019 Jul; 13(3):164-167. PubMed ID: 31257354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab.
    Sugano T; Seike M; Noro R; Kaburaki S; Tozuka T; Takahashi A; Takano N; Tanaka T; Kashiwada T; Takeuchi S; Minegishi Y; Saito Y; Kubota K; Terasaki Y; Gemma A
    Onco Targets Ther; 2018; 11():5879-5883. PubMed ID: 30271171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant treatment of pembrolizumab plus platinum-doublet chemotherapy in stage IIIA squamous cell carcinoma of the lung: a case report.
    Zhang C; Jiang W; Li G; Li J; Kang Y; Yu X; Ma H; Feng Y
    Ann Palliat Med; 2021 Mar; 10(3):3510-3517. PubMed ID: 33849133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re-challenge of immune checkpoint inhibitor pembrolizumab with concurrent tocilizumab after prior grade 3 pneumonitis.
    Nagpal C; Rastogi S; Shamim SA; Prakash S
    Ecancermedicalscience; 2023; 17():1644. PubMed ID: 38414933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy.
    Marandino L; Capozza A; Bandini M; Raggi D; Farè E; Pederzoli F; Gallina A; Capitanio U; Bianchi M; Gandaglia G; Fossati N; Colecchia M; Giannatempo P; Serafini G; Padovano B; Salonia A; Briganti A; Montorsi F; Alessi A; Necchi A
    Eur Urol Focus; 2021 Sep; 7(5):1092-1099. PubMed ID: 33172772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.
    Ksienski D; Wai ES; Croteau N; Freeman AT; Chan A; Fiorino L; Brooks EG; Poonja Z; Fenton D; Geller G; Irons S; Lesperance M
    Lung Cancer; 2019 Jul; 133():110-116. PubMed ID: 31200816
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab-induced Radiation Recall Pneumonitis After the Resolution of Typical Asymptomatic Radiation Pneumonitis.
    Itamura H; Ohguri T; Yahara K; Nakahara S; Kakinouchi S; Morisaki T; Yatera K; Tanaka F; Korogi Y
    J UOEH; 2020; 42(3):261-266. PubMed ID: 32879190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early presentation of pembrolizumab-associated pneumonitis.
    Christy J; Rafae A; Kandah E; Kunadi A
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34266820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pulmonary Sarcoidosis Activation following Neoadjuvant Pembrolizumab plus Chemotherapy Combination Therapy in a Patient with Non-Small Cell Lung Cancer: A Case Report.
    Fakhri G; Akel R; Salem Z; Tawil A; Tfayli A
    Case Rep Oncol; 2017; 10(3):1070-1075. PubMed ID: 29515398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab-induced severe oral mucositis in a patient with squamous cell carcinoma of the lung: A case study.
    Yoon SY; Han JJ; Baek SK; Kim HJ; Maeng CH
    Lung Cancer; 2020 Sep; 147():21-25. PubMed ID: 32652370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.
    O'Brien M; Paz-Ares L; Marreaud S; Dafni U; Oselin K; Havel L; Esteban E; Isla D; Martinez-Marti A; Faehling M; Tsuboi M; Lee JS; Nakagawa K; Yang J; Samkari A; Keller SM; Mauer M; Jha N; Stahel R; Besse B; Peters S;
    Lancet Oncol; 2022 Oct; 23(10):1274-1286. PubMed ID: 36108662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limb arteriolar vasculitis induced by pembrolizumab plus chemotherapy in a patient with lung cancer.
    Takada K; Hamatake M; Kohashi K; Shimamatsu S; Hirai F; Ohmori S; Tagawa T; Mori M
    Int Cancer Conf J; 2021 Jan; 10(1):83-86. PubMed ID: 33489708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab-induced aseptic meningitis in a patient with non-small cell lung cancer: A case report and literature review of aseptic meningitis as an immune-related adverse event.
    Inui G; Funaki Y; Makino H; Touge H; Arai K; Kuroda K; Hirayama Y; Kato R; Nonaka T; Yamane K; Teruya Y; Sueda Y; Sakamoto T; Yamaguchi K; Kodani M; Kawase S; Umekita Y; Horie Y; Nosaka K; Yamasaki A
    Mol Clin Oncol; 2022 Jul; 17(1):120. PubMed ID: 35747596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.